Ibalizumab is an investigational drug that is being studied for the treatment of HIV infection.
Ibalizumab belongs to a class (group) of HIV drugs called entry and fusion inhibitors. Entry and fusion inhibitors block HIV from getting into and infecting certain cells of the immune system. This prevents HIV from multiplying and can reduce the amount of HIV in the body.
Ibalizumab works by attaching to a protein on the surface of the immune cells. The protein is called the CD4 receptor. When ibalizumab attaches to the CD4 receptor, HIV cannot attach to, enter, or infect the cell.
Today it was announced that Danish biotech company Genmab has its 2nd cancer drug approved. The U.S. FDA has approved DARZALEX™ injection for intravenous infusion for the treatment of patients with multiple myeloma. Genmab almost doubled their estimate for 2015 with a milestones from Janssen of 45 USD Million. We are so happy on behalf […]
Company Announcement Submission of rolling BLA to US FDA for daratumumab in multiple myeloma completed by Janssen Biotech, Inc. Completion of submission triggers USD 15 million milestone payment to Genmab Copenhagen, Denmark; July 9, 2015 — Genmab A/S (OMX: GEN) announced its licensing partner Janssen Biotech, Inc. has completed the rolling submission of the Biologics License […]
Janssen has submitted a new Phase 4, early access treatment trial on Clinicaltrials. org the 15th June 2015. The objective of this study is to provide early access to daratumumab treatment and collect additional safety data while the medication is not commercially available for subjects with multiple myeloma who have received at least 3 prior lines of […]
Genmab held a presentation at Goldman Sachs 9th june 2015 following ASCO and recent BLA filing for Daratumumab. It was a 34 minute long Q&A session where we got some more insights in details in manufacturing and how Genmab sees the future for Daratumumab. The US plays a big role in any biotech and pharma […]